Molecular Medicine (MLM) Molmed (13 lettori)

cloca · 5 Aprile 2016

vediamo se il fib si fermerà a 16500

alicetta · 5 Aprile 2016

Reato ha scritto:
Pe quello che il titolo trema

volevo solo scimmiottare la Pasta Agnesi .... cacchio vuoi che dica il citrullo :ola:

cloca · 5 Aprile 2016

la concorrenza , anche se è indietro procede ..

7:06 am Bellicum Pharmaceuticals announces BPX-501 clinical data updates, studies selected for 2 oral presentations at Annual Meeting of European Society for Blood and Marrow Transplantation (BLCM) :

The BPX-501 trial is designed to evaluate whether this regimen is safe and improves immune reconstitution, infection control and overall outcomes.

In an oral presentation reviewing the preliminary outcomes from the BP-004 clinical trial in 17 high-risk pediatric patients with blood cancers, the data showed that BPX-501 cells expand in vivo and persist over time, contributing to adaptive immunity. There was no transplant-related mortality due to infections, GvHD or other transplant-related complications. Additionally, the relapse rate to date compares favorably with that of historical controls, with 16 of 17 patients in the trial with acute leukemias showing disease-free outcomes. The median follow-up period to date for these patients was ~seven months
"In both malignant and nonmalignant patients, the results show that treatment with BPX-501 appears safe, well-tolerated, and provides important immune benefits," commented Tom Farrell, President and CEO of Bellicum Pharmaceuticals. "These data also demonstrate high BPX-501 cell viability, expansion and persistence, and that the improvement of immune reconstitution is sustained. We look forward to sharing more results as these data mature, and providing updates following our plan to meet with the U.S. FDA and EMA during the second quarter of this year."